A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-101 in Adult Healthy Volunteers
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2018
At a glance
- Drugs ALPN 101 (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 19 Nov 2018 Status changed from planning to not yet recruiting.
- 24 Apr 2017 New trial record
- 18 Apr 2017 Accoording to a Nivalis Therapeutics media release, company plans to initiate this trial in the second half of 2018.